Boston Scientific(US:BSX) Ge Long Hui·2025-10-22 14:55Core Viewpoint - Boston Scientific (BSX.US) reported a strong performance in Q3, with sales exceeding analyst expectations and a significant year-over-year growth in revenue and adjusted earnings per share [1] Financial Performance - Q3 sales increased by 20% year-over-year to $5.07 billion, surpassing Wall Street's forecast of $4.97 billion [1] - The cardiovascular segment saw a 22% year-over-year sales growth, reaching $3.34 billion, which was above the expected $3.27 billion [1] - Adjusted earnings per share for the quarter were $0.75, exceeding the anticipated $0.71 [1] Guidance Update - The company raised its full-year adjusted earnings per share guidance to a range of $3.02 to $3.04, which is higher than the analyst consensus of $2.98 [1]